1.80 (-%)
As of May 24, 2024
Source:
We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it.
Country | United States |
Headquarters | boston, massachusetts |
Phone Number | 617-229-6499 |
Industry | |
CEO | Mark Smith, Ph.D. |
Website | clinicaltrials.gov |